Survival and time to progression according to predictors of response
. | Definition . | Median survival days (95% CI) . | P . | Median time to progression days (95% CI) . | P . |
---|---|---|---|---|---|
Response | SD or PD | 133 (114-152) | 75 (0-156) | ||
PR | 618 (554-682) | <0.001 | 451 (318-584) | <0.001 | |
Age (y) | ≤65 | 173 (97-249) | 382 (168-596) | ||
>65 | 187 (107-267) | = 0.273 | 243 (54-432) | = 0.639 | |
Sex | Male | 141 (112-170) | 299 (9-589) | ||
Female | 287 (205-369) | = 0.114 | 258 (245-271) | = 0.872 | |
Smoking | Smoker | 141 (112-170) | 243 (29-457) | ||
Never-smoked | 567 (17-1,117) | = 0.009 | 382 (91-673) | = 0.176 | |
Histologic type | Non-ADC | 133 (108-158) | 111 (38-184) | ||
ADC | 299 (156-442) | = 0.009 | 385 (211-559) | = 0.002 | |
EGFR expression | Grade 1-2 | 111 (50-172) | 111 (27-195) | ||
Grade 3-4 | 126 (33-219) | = 0.169 | 258 (0-539) | = 0.314 | |
EGFR mutation | Wild-type sequence | 143 (90-196) | 85 (17-153) | ||
Mutation | 567 (not calculated) | = 0.008 | 382 (187-577) | = 0.003 |
. | Definition . | Median survival days (95% CI) . | P . | Median time to progression days (95% CI) . | P . |
---|---|---|---|---|---|
Response | SD or PD | 133 (114-152) | 75 (0-156) | ||
PR | 618 (554-682) | <0.001 | 451 (318-584) | <0.001 | |
Age (y) | ≤65 | 173 (97-249) | 382 (168-596) | ||
>65 | 187 (107-267) | = 0.273 | 243 (54-432) | = 0.639 | |
Sex | Male | 141 (112-170) | 299 (9-589) | ||
Female | 287 (205-369) | = 0.114 | 258 (245-271) | = 0.872 | |
Smoking | Smoker | 141 (112-170) | 243 (29-457) | ||
Never-smoked | 567 (17-1,117) | = 0.009 | 382 (91-673) | = 0.176 | |
Histologic type | Non-ADC | 133 (108-158) | 111 (38-184) | ||
ADC | 299 (156-442) | = 0.009 | 385 (211-559) | = 0.002 | |
EGFR expression | Grade 1-2 | 111 (50-172) | 111 (27-195) | ||
Grade 3-4 | 126 (33-219) | = 0.169 | 258 (0-539) | = 0.314 | |
EGFR mutation | Wild-type sequence | 143 (90-196) | 85 (17-153) | ||
Mutation | 567 (not calculated) | = 0.008 | 382 (187-577) | = 0.003 |
Abbreviations: CI, confidence interval; SD, stable disease; PD, progressive disease; PR, partial remission; ADC, adenocarcinoma.